Guggenheim lowered the firm’s price target on Olema Oncology (OLMA) to $35 from $38 and keeps a Buy rating on the shares. The firm, which has updated its model for expense trends, says “the key learning” from near-term monotherapy OP-3136 data at ASCO 2026 will be safety versus Pfizer’s (PFE) KAT6 that reports high-dose reductions, especially due to cytopenias and dysgeusia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals: Differentiated KAT6i and Palazestrant Pipeline Catalysts Underpin Buy Rating
- Olema Oncology reports Q1 EPS (52c), consensus (54c)
- Olema Pharmaceuticals Signs New Headquarters Lease at Oyster Point
- Olema Pharmaceuticals Adds Veteran Director to Support Growth
- Olema Oncology to present initial clinical data for OP-3136 at ASCO